NPI: 1104262286 · GREELEY, CO 80634 · Emergency Care Clinic/Center · NPI assigned 05/16/2013
Authorized official THOMPSON, DAVID controls 20+ related entities in our dataset. Read more
| Authorized Official | THOMPSON, DAVID (CFO) |
| Parent Organization | MEDICAL CENTER OF THE ROCKIES |
| NPI Enumeration Date | 05/16/2013 |
Other providers sharing the same authorized official: THOMPSON, DAVID
| Year | Claims | Total Paid |
|---|---|---|
| 2019 | 288 | $19K |
| 2020 | 1,667 | $88K |
| 2021 | 4,533 | $332K |
| 2022 | 9,109 | $662K |
| 2023 | 6,669 | $528K |
| 2024 | 2,782 | $214K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 11,836 | 10,934 | $1.50M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 928 | 854 | $117K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1,259 | 1,179 | $100K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 904 | 782 | $77K |
| 96361 | Intravenous infusion, hydration; each additional hour | 51 | 51 | $18K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 148 | 146 | $12K |
| 80047 | 1,205 | 1,115 | $8K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 63 | 53 | $6K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 50 | 39 | $3K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 131 | 111 | $537.06 |
| J3490 | Unclassified drugs | 5,579 | 3,756 | $476.37 |
| 80053 | Comprehensive metabolic panel | 14 | 14 | $462.80 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 21 | 13 | $413.19 |
| 85027 | 1,156 | 1,077 | $183.46 | |
| 81003 | 665 | 613 | $100.74 | |
| 71045 | Radiologic examination, chest; single view | 12 | 12 | $55.97 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 349 | 326 | $15.80 |
| 82977 | 14 | 14 | $0.00 | |
| 84155 | 14 | 14 | $0.00 | |
| 82247 | 14 | 14 | $0.00 | |
| 81025 | 64 | 61 | $0.00 | |
| 84460 | 14 | 14 | $0.00 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 56 | 45 | $0.00 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 29 | 16 | $0.00 |
| 84450 | 14 | 14 | $0.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 12 | 12 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 135 | 133 | $0.00 |
| J8597 | Antiemetic drug, oral, not otherwise specified | 13 | 12 | $0.00 |
| 81001 | 36 | 26 | $0.00 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 182 | 159 | $0.00 |
| 82150 | 14 | 14 | $0.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 38 | 26 | $0.00 |
| 84075 | 14 | 14 | $0.00 | |
| 82040 | 14 | 14 | $0.00 |